ArticleGlobalization and health2017
Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
Article in Globalization and health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global, regional and national availability of essential medicines for children, 2009-2020: a systematic review and meta-analysis.BMC public health · 2023Pooled it
- A systematic review of pooled procurement of medicines and vaccines: identifying elements of success.Globalization and health · 2022Pooled it
- Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Reconceptualizing access: advancing pharmaceutical equity for health system resilience in Central and South America.Lancet regional health. Americas · 2026Article
- The availability of essential medicines in public healthcare facilities in Afghanistan: navigating sociopolitical and geographical challenges.Health policy and planning · 2025Article
- Medicines policy, access and use in Mexico: a systematic literature review 2000-2022.Drugs in context · 2024Review
- The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.Journal of global health · 2023Article
- How National Health Insurance Coverage Policy Affected the Use of Trastuzumab and Rituximab in China: A Bicentric Retrospective Study.Risk management and healthcare policy · 2023Article
- Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru.Journal of pharmaceutical policy and practice · 2022Article
- Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.Frontiers in public health · 2022Article
- Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.Applied health economics and health policy · 2022Article
- Interest in Receiving HIV PrEP Among Biological Male Latinx Migrants at High-Risk of HIV Living in Mexico.Journal of health care for the poor and underserved · 2022Article
- Availability, pricing and affordability of essential medicines in Eastern Ethiopia: a comprehensive analysis using WHO/HAI methodology.Journal of pharmaceutical policy and practice · 2021Article
- The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.BMJ global health · 2021Article
- Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.BMC health services research · 2020Article
- Article
- The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data.PloS one · 2019Article
- Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis.Global health action · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization recommends establishing and implementing a national pharmaceutical policy (NPP) to guarantee effective and equitable access to medicines. Mexico has implemented several policy approaches to regulate the pharmaceutical sector, but it has no formal NPP. This article describes the approach that the Mexican government has taken to improve availability and affordability of essential medicines.
methodsDescriptive policy analysis of public pharmaceutical policy proposals and health action plans on the basis of publicly available data and health progress reports, with a focus on availability and affordability of medicines.
resultsThe government has implemented pooled procurement, price negotiations, and an information platform in the public sector to improve affordability and availability. The government mainly reports on the savings that these strategies have generated in the public expenditure but their full impact on availability and affordability has not been assessed.
conclusionsTo increase availability and affordability of medicines in the public sector, the Mexican government has resorted on isolated strategies. In addition to efficient procurement, price negotiations and price information, other policy components and pricing interventions are needed. All these strategies should be included in a comprehensive NPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.